Preservation of CD34+ Stem Cells and Precursors with TransFix

CD34+ population enumeration has multiple applications, for example to indicate whether a hematopoietic stem-cell harvest is ready to be performed for transplant, or to characterise progenitor/precursor populations such as B-cell precursors in Acute lymphoblastic leukaemia (ALL) samples. However, rare CD34+ populations can be hard to define due to sample degradation.

There are several references where researchers analyse CD34+ populations with TransFix-treated samples. Below we highlight a few publications that analyse CD34+ cells in TransFix-treated samples:

Reducing Inter-Institutional Variability of CD34+ Stem Cell Enumeration

Successful hematopoietic stem cell (HSC) transplantation for malignant and nonmalignant hematologic diseases relies on accurate stem cell counting. CD34+ analysis is a rapid method of enumeration, but variability has historically been high between analysis at different institutions. Lysák et al. (2010) and Levering et al. (2007) have  performed external quality assurance (EQA) studies concerning the interlaboratory variability of CD34+ enumeration. Both groups used TransFix to stabilise mobilized peripheral blood as reference material to send out to all participating laboratories.

  • Lysák et al (2010) Interlaboratory variability of CD34+ stem cell enumeration. A pilot study to national external quality assessment within the Czech Republic. Int. Jnl. Lab. Hem. 32, e229–e236.
  • Levering et al. (2007) Flow Cytometric CD34+ Stem Cell Enumeration: Lessons from Nine Years’ External Quality Assessment Within the Benelux Countries. Cytometry Part B (Clinical Cytometry) 72B: 178–188.

Analysis of CD34+ B-Cell Precursors in CSF Samples

TransFix has been widely used to stabilise Cerebrospinal Fluid (CSF) samples with suspected haematological malignancies such as B-cell ALL. To define B-Cell Precursors, CD34+ is often analysed. Because of the fragile nature and low number of cells present in CSF, TransFix is used to preserve these cells.

There are several papers referencing CD34+ analysis on CSF Samples. For a full list of references, view our list of compatible markers. To name a few:

  • Thastrup et al. (2019) Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study. Leukemia 34: 336–346.
  • Levinsen et al (2016) Leukemic blasts are present at low levels in spinal fluid in one-third of childhood acute lymphoblastic leukemia cases. Pediatr Blood Cancer 63; 1935–1942.

Preservation of Bone Marrow CD34+ Stem Cells

Beiral et al. aimed to show the administration of bone marrow-derived stem cells (BMSCs) can aid recovery of mitochondrial respiration following ischemia/reperfusion (I/R) injuries. Rat BMSCs  were used immediately following isolation from the extracted bone marrow and some were retained for characterisation. 3×106 of the BMSCs were resuspended in PBS and stabilised using 1 part TransFix to 5 parts cell suspension for subsequent immunophenotyping, allowing the researchers to complete other time sensitive aspects of the study. Long Term hematopoietic stem cells were defined as CD45+/CD34+/CD90.1+; short term defined as CD45+/CD34+/CD90.1-.

  • Beiral et al. (2014) The impact of stem cells on electron fluxes, proton translation, and ATP synthesis in kidney mitochondria after ischemia/reperfusion. Cell Transplant 23(2): 207-20.

Stabilisation of CD34+ Circulating Progenitor Endothelial Cells Populations

CD34+ Circulating Progenitor Endothelial Cells are discussed in a previous blog, found here.
For more examples of publications referencing the use of TransFix, visit our bibliography section!

View Bibliography

TransFix Products

TransFix® has been validated with a number of specific sample types and optimised with specially designed sample collection tubes:

If you have a problem with sample degradation in your research, contact us to see if TransFix could help.

About the Author